MedTrace Logo

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NCT04529473 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-11-15

No results posted yet for this study

Summary

This 12 week placebo-controlled study evaluates the efficacy and safety of E. hallii supplementation.

Conditions

  • Pre Diabetes
  • Impaired Glucose Tolerance
  • Insulin Sensitivity
  • Insulin Resistance
  • Glucose Metabolism Disorders
  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Eubacterium hallii

Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)

OTHER

Placebo

Placebo capsules are identical to the active treatment

Sponsors & Collaborators

  • Caelus Pharmaceuticals BV

    collaborator INDUSTRY

  • Atlantia Food Clinical Trials

    lead INDUSTRY

Principal Investigators

  • James Ryan, MD · Atlantia Food Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-03
Primary Completion
2022-08-23
Completion
2022-08-23

Countries

  • United States
  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04529473 on ClinicalTrials.gov